UBS Group’s Orchard Therapeutics plc American Depositary Shares ORTX Stock Holding History

UBS Group’s Portfolio ORTX Stock Details ORTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,000	Closed	-$79K	–	11177
2021 Q4	$79K	Buy	+6,000	New	+$99.2K	﹤0.01%	6512

UBS Group's ORTX Position: Q1 2024 in Review

UBS Group sold out of Orchard Therapeutics plc American Depositary Shares (ORTX) in Q1 2024, closing a stake of 380 shares — an estimated $6.25K sold.

UBS Group first reported a position in ORTX in Q4 2018 and held it in 21 quarters. The position peaked at $786K in Q1 2021. 0 funds tracked by Wall St. Rank hold ORTX as of Q1 2024.

UBS Group reported no remaining Orchard Therapeutics plc American Depositary Shares position as of Q1 2024 after selling out during the quarter.
UBS Group sold 380 Orchard Therapeutics plc American Depositary Shares shares in Q1 2024, an estimated $6.25K.
UBS Group first reported a position in Orchard Therapeutics plc American Depositary Shares in Q4 2018 and held it in 21 quarters.
UBS Group's Orchard Therapeutics plc American Depositary Shares position peaked at $786K in Q1 2021.
0 funds tracked by Wall St. Rank held Orchard Therapeutics plc American Depositary Shares as of Q1 2024.

Based on UBS Group's 13F filing for Q1 2024, filed 13 May 2024.